

May 15, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

Email: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Announcement of Presentation of Aggressive NK-cell Leukemia (ANKL) at EHA\*2024 Hybrid Congress**

Perseus Proteomics Inc. ("the Company") is pleased to announce that the abstract of ANKL presentation by Specially Appointed Associate Professor (Full Time) Ryo Yanagiya and Professor Ai Kotani, the joint research partners of the Company, has been accepted by EHA2024 Hybrid Congress to be held in Madrid, Spain and that it is now available online.

Date: June 13-16, 2024

Title: AMINO ACID INFLUX VIA LAT1 REGULATES IRON DEPENDENCY OF AGGRESSIVE NATURAL KILLER CELL LEUKEMIA

Poster No: P1250

Presenter: Specially Appointed Associate Professor (Full Time) Ryo Yanagiya (Osaka University) and Professor Ai Kotani (Osaka University)

URL: [https://library.ehaweb.org/eha/2024/eha2024-congress/419337/ryo.yanagiya.amino.acid.influx.via.lat1.regulates.iron.dependency.of.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace\\_id%3D2552%2Aot\\_id%3D29172%2Amarker%3D5101%2Afeatured%3D18498](https://library.ehaweb.org/eha/2024/eha2024-congress/419337/ryo.yanagiya.amino.acid.influx.via.lat1.regulates.iron.dependency.of.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29172%2Amarker%3D5101%2Afeatured%3D18498)

This research leads to elucidation of mechanism of action of PPMX-T003 and LAT1, one of amino acid transporters, is expected to be an effective biomarker to predetermine the effectiveness of ANKL therapy.

\*EHA: European Hematology Association